Effect of apo E phenotype on plasma postprandial triglyceride levels in young male adults with and without a familial history of myocardial infarction: The EARS II study

Atherosclerosis

Volumn 145, Issue 2, 1999, Pages 381-388

  Dallongeville, J ^a   Tiret, L ^b   Visvikis, S ^c   O'Reilly, D St J ^d   Saava, M ^e   Tsitouris, G ^f   Rosseneu, M ^g   DeBacker, G ^g   Humphries, S E ^h   Beisiegel, U ⁱ  

^a INSTITUT PASTEUR DE LILLE   (France)

^b HÔPITAL BROUSSAIS   (France)

^c Centre de Medecine Preventive   (France)

^d GLASGOW ROYAL INFIRMARY   (United Kingdom)

^e Estonian Institute of Cardiology   (Estonia)

^f EVANGELISMOS HOSPITAL   (Greece)

^g GHENT UNIVERSITY   (Belgium)

^h UNIVERSITY COLLEGE LONDON   (United Kingdom)

ⁱ UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Apolipoprotein; Genetics; Myocardial infarction; Postprandial metabolism; Triglycerides

Indexed keywords

APOLIPOPROTEIN E; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ADULT; ARTICLE; CONTROLLED STUDY; FAMILY HISTORY; HEART INFARCTION; HUMAN; HUMAN EXPERIMENT; HYPERTRIGLYCERIDEMIA; LIPID BLOOD LEVEL; LIPID METABOLISM; MALE; NORMAL HUMAN; PHENOTYPE; POSTPRANDIAL STATE; PRIORITY JOURNAL; PROTEIN POLYMORPHISM; RISK FACTOR;

ADOLESCENT; ADULT; ALLELES; APOLIPOPROTEINS E; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DIETARY FATS; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PHENOTYPE; POLYMORPHISM, GENETIC; POSTPRANDIAL PERIOD; RISK FACTORS; TRIGLYCERIDES;

EID: 0032788264     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(99)00069-6     Document Type: Article

References (53)

1. Noncommunicable diseases: a global problem. World Health Statistics Quarterly 1988;41:160.
2. Barrett-Connor E, Khaw K. Family history of heart attack as an independent predictor of death due to cardiovascular disease. Circulation 1984;69:1065-9.
3. Breslow JL, Dammerman M. Genetic determinants of myocardial infarction. Adv Exp Med Biol 1995;369:65-78.
4. Humphries SE. Life style, genetic factors and the risk of heart attack: the apolipoprotein B gene as an example. Biochem Soc Trans 1993;21:569-82.
5. De Backer G, Hulstaert F, De Munck K, Rosseneu M, Van Parijs L, Dramaix M. Serum lipids and apoproteins in students whose parents suffered prematurely from a myocardial infarction. Am Heart J 1986;112:478-84.
6. Sniderman A, Teng B, Genest J, Cianflone K, Wacholder S, Kwiterovich PJ. Familial aggregation and early expression of hyperapobetalipoproteinemia. Am J Cardiol 1985;55: 291-5.
7. Cambien F, Warnet JM, Jacqueson A, Ducimetiere P, Richard JL, Claude JR. Relation of parental history of early myocardial infarction to the level of apoprotein B in men. Circulation 1987;76:266-71.
8. Freedman DS, Srinivasan SR, Shear CL, Franklin FA, Webber LS, Berenson GS. The relation of apolipoproteins A-I and B in children to parental myocardial infarction. New Engl J Med 1986;315:721-6.
9. Takahashi A, Terai Y, Taniguchi S, Fujiwara T. Plasma lipids, lipoproteins, apolipoprotein A-I and A-II concentrations in children with familial history of premature ischemic heart disease. In: Lovenberg W, Yamori Y, editors. Nutritional Prevention of Cardiovascular Disease. Orlando, FL: Academic Press Inc, 1984:259-66.
10. Amouyel P, Isorez D, Bard JM, Goldman M, Lebel P, Zylberberg G, Fruchart JC. Parental history of early myocardial infarction is associated with decreased levels of lipoparticle AI in adolescents. Arterioscler Thromb 1993;13:1640-4.
11. Rosseneu M, De Backer G, Caster H, Hulstaert F, Bury J. Distribution and composition of HDL subclasses in students whose parents suffered prematurely from a myocardial infarction in comparison with controls. Atherosclerosis 1987;63:231-4.
12. The European Atherosclerosis Research Study (EARS). Design and objectives. Int J Epidemiol 1994;23:465-71.
13. Rosseneu M, Fruchart JC, Bard JM, Nicaud V, Vinaimont N, Cambien F, De Backer G. Plasma apolipoprotein concentrations in young adults with a parental history of premature coronary heart disease and in control subjects. The EARS Study. European Atherosclerosis Research Study. Circulation 1994;89:1967-73.
14. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta- analysis of population-based prospective studies. J Cardiovasc Risk 1996;3:213-9.
15. Zilversmit DB. Atherogenesis: a postprandial phenomenon. Circulation 1979;60:473-85.
16. Havel RJ. Postprandial hyperlipidemia and remnant lipoproteins. Curr Opin Lipidol 1994;5:102-9.
17. Dart A, Sherrard B, Simpson H. Influence of apo E phenotype on postprandial triglyceride and glucose responses in subjects with and without coronary heart disease. Atherosclerosis 1997;130:161-70.
18. Nikkila M, Solakivi T, Lehtimaki T, Koivula T, Laippala P, Astrom B. Postprandial plasma lipoprotein changes in relation to apolipoprotein E phenotypes and low density lipoprotein size in men with and without coronary artery disease. Atherosclerosis 1994;106:149-57.
19. Patsch JR, Miesenbock G, Hopferwieser T, Muhlberger V, Knapp E, Dunn JK, Gotto AMJ, Patsch W. Relation of triglyceride metabolism and coronary artery disease. Studies in the postprandial state. Arterioscler Thromb 1992;12:1336-45.
20. Simpson HS, Williamson CM, Olivecrona T, Pringle S, Maclean J, Lorimer AR, Bonnefous F, Bogaievsky Y, Packard CJ, Shepherd J. Postprandial lipemia, fenofibrate and coronary artery disease. Atherosclerosis 1990;85:193-202.
21. Katzel LI, Busby-Whitehead MJ, Rogus EM, Krauss RM, Goldberg AP. Reduced adipose tissue lipoprotein lipase responses, postprandial lipemia, and low high-density lipoprotein-2 subspecies levels in older athletes with silent myocardial ischemia. Metabolism 1994;43:190-8.
22. Simons LA, Dwyer T, Simons J, Bernstein L, Mock P, Poonia NS, Balasubramaniam S, Baron D, Branson J, Morgan J. Chylomicrons and chylomicron remnants in coronary artery disease: a case-control study. Atherosclerosis 1987;65:181-9.
23. Karpe F, Steiner G, Uffelman K, Olivecrona T, Hamsten A. Postprandial lipoproteins and progression of coronary atherosclerosis. Atherosclerosis 1994;106:83-97.
24. Meyer E, Westerveld HT, de Ruyter-Meijstek FC, van Greevenbroek MM, Rienks R, van Rijn HJ, Erkelens DW, de Bruin TW. Abnormal postprandial apolipoprotein B-48 and triglyceride responses in normolipidemic women with greater than 70% stenotic coronary artery disease: a case-control study. Atherosclerosis 1996;124:221-35.
25. Groot PH, van Stiphout WA, Krauss XH, Jansen H, van Tol A, van Ramshorst E, Chin-On S, Hofman A, Cresswell SR, Havekes L. Postprandial lipoprotein metabolism in normolipidemic men with and without coronary artery disease. Arterioscler Thromb 1991;11:653-62.
26. Weintraub MS, Grosskopf I, Rassin T, Miller H, Charach G, Rotmensch HH, Liron M, Rubinstein A, Iaina A. Clearance of chylomicron remnants in normolipidaemic patients with coronary artery disease: case control study over three years. Br Med J 1996;312:936-9.
27. Hughes TA, Elam MB, Applegate WB, Bond MG, Hughes SM, Wang X, Tolley EA, Bittle JB, Stentz FB, Kang ES. Postprandial lipoprotein responses in hypertriglyceridemic subjects with and without cardiovascular disease. Metabolism 1995;44:1082-98.
28. Schneider WJ, Kovanen PT, Brown MS, Goldstein JL, Utermann G, Weber W, Havel RJ, Kotite L, Kane JP, Innerarity TL, Mahley RW. Familial dysbetalipoproteinemia. Abnormal binding of mutant apoprotein E to low density lipoprotein receptors of human fibroblasts and membranes from liver and adrenal of rats, rabbits, and cows. J Clin Invest 1981;68:1075-85.
29. Al-Haideri M, Goldberg IJ, Galeano NF, Gleeson A, Vogel T, Gorecki M, Sturley SL, Deckelbaum RJ. Heparan sulfate proteoglycan-mediated uptake of apolipoprotein E-triglyceride-rich lipoprotein particles: a major pathway at physiological particle concentrations. Biochemistry 1997;36:12766-72.
30. Steinmetz A, Jakobs C, Motzny S, Kaffarnik H. Differential distribution of apolipoprotein E isoforms in human plasma lipoproteins. Arteriosclerosis 1989;9:405-11.
31. Brenninkmeijer BJ, Stuyt PM, Demacker PN, Stalenhoef AF, van't Laar A. Catabolism of chylomicron remnants in normolipidemic subjects in relation to the apoprotein E phenotype. J Lipid Res 1987;28:361-70.
32. Weintraub MS, Eisenberg S, Breslow JL. Dietary fat clearance in normal subjects is regulated by genetic variation in apolipoprotein. Eur J Clin Invest 1987;80:1571-7.
33. Boerwinkle E, Brown S, Sharrett AR, Heiss G, Patsch W. Apolipoprotein E polymorphism influences postprandial retinyl palmitate but not triglyceride concentrations. Am J Hum Genet 1994;54:341-60.
34. Orth M, Wahl S, Hanisch M, Friedrich I, Wieland H, Luley C. Clearance of postprandial lipoproteins in normolipemics: role of the apolipoprotein E phenotype. Biochim Biophys Acta 1996;1303:22-30.
35. Brown AJ, Roberts DC. The effect of fasting triacylglyceride concentration and apolipoprotein E polymorphism on postprandial lipemia. Arterioscler Thromb 1991;11:1737-44.
36. Reznik Y, Pousse P, Herrou M, Morello R, Mahoudeau J, Drosdowsky MA, Fradin S. Postprandial lipoprotein metabolism in normotriglyceridemic non-insulin- dependent diabetic patients: influence of apolipoprotein E polymorphism. Metabolism 1996;45:63-71.
37. Superko HR, Haskell WL. The effect of apolipoprotein E isoform difference on postprandial lipoprotein in patients matched for triglycerides, LDL-cholesterol, and HDL-cholesterol. Artery 1991;18:315-25.
38. Bergeron N, Havel RJ. Prolonged postprandial responses of lipids and apolipoproteins in triglyceride-rich lipoproteins of individuals expressing an apolipoprotein ε4 allele. J Clin Invest 1996;97:65-72.
39. Regis-Bailly A, Visvikis S, Steinmetz J, Fournier B, Gueguen R, Siest G. Effects of apo B and apo E gene polymorphisms on lipid and apolipoprotein concentrations after a test meal. Clin Chim Acta 1996;253:127-43.
40. Wilson PW, Schaefer EJ, Larson MG, Ordovas JM. Apolipoprotein E alleles and risk of coronary disease. A meta-analysis. Arterioscler Thromb Vasc Biol 1996;16:1250-5.
41. The EARS Study. The distribution of fasting plasma lipid concentrations in the offspring of men with premature coronary heart disease in Europe. Int J Epidemiol 1994;23: 472-81.
42. Tiret L, Murphy SP, Gerdes C, et al. Postprandial responses to glucose and fat tolerance tests in young adults with a parental history of premature coronary heart disease-the EARS II study. 1998; (submitted)
43. Bury J, Vercaemst R, Rosseneu M, Belpaire F. Apolipoprotein E quantified by enzyme-linked immunosorbent assay. Clin Chem 1986;32:265-70.
44. Siedel J, Schiefer S, Rosseneu M, Bergeaud R, De Keersgieter W, Pautz B, Vinaimont N, Ziegenhorn J. Immunoturbidimetric method for routine determinations of apolipoproteins A-I, A-II, and B in normo- and hyperlipemic sera compared with immunonephelometry. Clin Chem 1988;34:1821-5.
45. Havekes LM, de Knijff P, Beisiegel U, Havinga J, Smit M, Klasen E. A rapid micromethod for apolipoprotein E phenotyping directly in serum. J Lipid Res 1987;28:455-63.
46. Menzel HG, Utermann G. Apolipoprotein phenotyping from serum by Western blotting. Electrophoresis 1986;7:492-5.
47. Davignon J, Gregg RE, Sing CF. Apolipoprotein E polymorphism and atherosclerosis. Arteriosclerosis 1988;8:1-21.
48. Tiret L, de Knijff P, Menzel HJ, Ehnholm C, Nicaud V, Havekes LM. Apo E polymorphism and predisposition to coronary heart disease in youths of different European populations. The EARS Study. European Atherosclerosis Research Study. Arterioscler Thromb 1994;14:1617-24.
49. Xu CF, Talmud PJ, Angelico F, Del Ben M, Savill J, Humphries SE. Apolipoprotein E polymorphism and plasma lipid, lipoprotein, and apolipoprotein levels in Italian children. Genet Epidemiol 1991;8:389-98.
50. Lehtimaki T, Moilanen T, Viikari J, Akerblom HK, Ehnholm C, Ronnemaa T, Marniemi J, Dahlen G, Nikkari T. Apolipoprotein E phenotypes in Finnish youths: a cross-sectional and 6-year follow-up study. J Lipid Res 1990;31:487-95.
51. Karpe F, Bell M, Bjorkegren J, Hamsten A. Quantification of postprandial triglyceride-rich lipoproteins in healthy men by retinyl ester labeling and simultaneous measurement of apolipoproteins B-48 and B-100. Arterioscler Thromb Vasc Biol 1995;15:199-207.
52. Dallongeville J, Lussier-Cacan S, Davignon J. Modulation of plasma triglyceride levels by apo E phenotype: a meta- analysis. J Lipid Res 1992;33:447-54.
53. Rensen PN, van Berkel TC. Apolipoprotein E effectively inhibits lipoprotein lipase-mediated lipolysis of chylomicron-like triglyceride-rich lipid emulsions in vitro and in vivo. J Biol Chem 1996;271:14791-9.